Welcome to the HDlighthouse! Getting started.
|
New to the Huntington's Disease Lighthouse? Welcome to the HDlighthouse! Getting started.
|
||
 |
 |
 |
|
 |
|
 |
 |
 |
 |
 |
|
 |
|
|
 |
Drugs and SupplementsThis page focuses on research related to drugs and supplements that may delay onset and slow progression of Huntington's Disease. |
Research focusing on the formation of aggregates caused by HD
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
Research related HD and it's general affect on the brain
Learn more about the clinical trial process, trials that have been conducted and those that are underway.
Research focusing on gene therapy.
Research focusing on gene transcription.
General research related to HD
Research studying the genetics of Huntington's Disease
Research studying the Immune System and it's effect on the progression of HD
Research studying the brain tissue and research related to stem cells
19 Jul 2008
The FDA approves a Phase IIB clinical trial for ACR16
Neurosearch will begin recruiting for the trial later this year. 7 Jul 2008
Encouraging results from the Phase II Dimebon trial
Dimebon was found to be safe and well tolerated and there are indications of effectiveness. 24 Mar 2008
Approved drugs found to induce autophagy
UK researchers have found promising drugs which induce autophagy, an alternate way to clear away the HD protein. 5 Jan 2008
Zoloft raises BDNF, helps the HD mice
Sertaline (Zoloft) improves symptoms, reduces brain atrophy, and prolongs survival in the R6/2 mice. 1 Jan 2008
Screening Yields a Promising Compound
High throughput screening has identified a compound which inhibits protein aggregation. Part 1 of 3. 1 Jan 2008
C2-8 Suppresses Neurodegeneration in Drosophilia
C2-8 moves another step on the research pipeline with success in a fruitfly model of HD. Part 2 of 3. 1 Jan 2008
C2-8 Slows Progression in HD Mice
R6/2 mice given C2-8 experience delayed progression of motor symptoms and reduced cell death. Part 3 of 3 4 Dec 2007
Buck Institute and Neurobiological Technologies, Inc. Partner to Develop Treatment for HD
Following promising results in mouse models, researchers at Buck Institute and NTI will work on developing FGF-2 as a drug for HD patients. 19 Nov 2007
Miraxion results look promising
One more Phase III clinical trial is needed to support a New Drug Application. 8 Nov 2007
Minocycline accelerates ALS progression
A Phase III clinical trial of 400 mg per day of minocycline accelerated disease progression in ALS patients. All Updates for Drugs and Supplements |
 |
Disclaimer & Privacy
Policy |
Welcome | 
Site Feedback Marsha@HDLighthouse.org
|
